BINEX Co. Ltd Cash Flow Conversion Efficiency
BINEX Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, BINEX Co. Ltd (053030) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.62 Billion ≈ $2.45 Million USD) by net assets (₩187.21 Billion ≈ $126.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 053030 stock market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of BINEX Co. Ltd (2005–2024)
Cash flow conversion efficiency of BINEX Co. Ltd from 2005 to 2024. This chart illustrates how BINEX Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of BINEX Co. Ltd for real-time trading data and today's change.
BINEX Co. Ltd Cash Flow Conversion Ratio Explained
BINEX Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BINEX Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BINEX Co. Ltd ranked by their cash flow conversion efficiency. Review BINEX Co. Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
0.021x |
|
China Automotive Systems Inc
NASDAQ:CAAS
|
0.048x |
|
FinLab AG
F:A7A
|
0.013x |
|
Tecogen Inc.
NYSE:TGEN
|
-0.120x |
|
Paragon Care Limited
F:PXS
|
0.001x |
|
UVAT Technology Co Ltd
TWO:3580
|
0.047x |
|
Grupo Clarin S.A.
BA:GCLA
|
-0.134x |
|
It's Skin Co Ltd
KO:226320
|
0.010x |
Annual Cash Flow Conversion Efficiency for BINEX Co. Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of BINEX Co. Ltd from 2005 to 2024. Also see balance sheet size of BINEX Co. Ltd for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩181.61 Billion ≈ $123.07 Million |
₩-9.43 Billion ≈ $-6.39 Million |
-0.052x | -349.11% |
| 2023-12-31 | ₩181.33 Billion ≈ $122.88 Million |
₩3.78 Billion ≈ $2.56 Million |
0.021x | -76.60% |
| 2022-12-31 | ₩191.61 Billion ≈ $129.85 Million |
₩17.06 Billion ≈ $11.56 Million |
0.089x | -42.77% |
| 2021-12-31 | ₩180.42 Billion ≈ $122.27 Million |
₩28.07 Billion ≈ $19.02 Million |
0.156x | +35.30% |
| 2020-12-31 | ₩173.22 Billion ≈ $117.39 Million |
₩19.92 Billion ≈ $13.50 Million |
0.115x | +71.13% |
| 2019-12-31 | ₩160.50 Billion ≈ $108.77 Million |
₩10.78 Billion ≈ $7.31 Million |
0.067x | -25.95% |
| 2018-12-31 | ₩149.43 Billion ≈ $101.27 Million |
₩13.56 Billion ≈ $9.19 Million |
0.091x | +43.61% |
| 2017-12-31 | ₩128.75 Billion ≈ $87.25 Million |
₩8.14 Billion ≈ $5.51 Million |
0.063x | +133.80% |
| 2016-12-31 | ₩140.55 Billion ≈ $95.25 Million |
₩3.80 Billion ≈ $2.57 Million |
0.027x | +186.63% |
| 2015-12-31 | ₩144.14 Billion ≈ $97.68 Million |
₩-4.50 Billion ≈ $-3.05 Million |
-0.031x | -64.56% |
| 2013-12-31 | ₩97.45 Billion ≈ $66.04 Million |
₩-1.85 Billion ≈ $-1.25 Million |
-0.019x | -206.41% |
| 2011-12-31 | ₩70.58 Billion ≈ $47.83 Million |
₩1.26 Billion ≈ $852.26K |
0.018x | -80.30% |
| 2007-12-31 | ₩34.50 Billion ≈ $23.38 Million |
₩3.12 Billion ≈ $2.11 Million |
0.090x | +14.74% |
| 2006-12-31 | ₩31.91 Billion ≈ $21.62 Million |
₩2.52 Billion ≈ $1.70 Million |
0.079x | +54.89% |
| 2005-12-31 | ₩28.99 Billion ≈ $19.64 Million |
₩1.48 Billion ≈ $999.86K |
0.051x | -- |
About BINEX Co. Ltd
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more